In vitro and in vivo activities of novel 6-methylidene penems as β-lactamase inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 12, 2004, Pages 4589-4596

  Weiss, William J ^a,e   Petersen, Peter J ^a,d   Murphy, Timothy M ^a   Tardio, LuAnna ^a   Yang, Youjun ^a   Bradford, Patricia A ^a   Venkatesan, Aranapakam M ^a   Abe, Takao ^b   Isoda, Takeshi ^b   Mihira, Ado ^b   Ushirogochi, Hideki ^b   Takasake, Tsuyoshi ^b   Projan, Steve ^c   O'Connell, John ^a   Mansour, Tarek S ^a  

^a WYETH RESEARCH   (United States)

^b Department of Pharmacokinetics   (Japan)

^c PFIZER INC   (United States)

^d NONE   (United States)

^e Cumbre Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; IMIPENEM; PENEM DERIVATIVE; PEPTIDASE; PIPERACILLIN; TAZOBACTAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; CITROBACTER; CLEARANCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SENSITIVITY; ENTEROBACTER; ENZYME ACTIVITY; ESCHERICHIA COLI; FEMALE; IN VITRO STUDY; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; MALE; MINIMUM INHIBITORY CONCENTRATION; MOLECULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SERRATIA;

ANIMALS; AREA UNDER CURVE; BACTERIA; BACTERIAL INFECTIONS; BETA-LACTAMASES; BETA-LACTAMS; BICYCLO COMPOUNDS; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; FEMALE; HETEROCYCLIC COMPOUNDS; KINETICS; MICE; MICROBIAL SENSITIVITY TESTS; PENICILLINS; PIPERACILLIN; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 9644295781     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.12.4589-4596.2004     Document Type: Article

References (40)

1. Adachi, H., Y. Tawaragi, C. Inuzuka, I. Kubota, M. Tsujimoto, T. Nishihara, and H. Nakazato. 1990. Primary structure of human microsomal dipeptidase deduced from molecular cloning. J. Biol. Chem. 265:3992-3995.
2. Bauernfeind, A., Y. Chong, and K. Lee. 1998. Plasmid-encoded AmpC beta-lactamases: how far have we gone 10 years after the discovery? Yonsei Med. J. 39:520-525.
3. Bedini, A., C. Balsamini, B. Di Giacomo, A. Tontini, B. Citterio, L. Giorgi, E. Di Modugno, and G. Tarzia. 2002. Synthesis and biological evaluation of 6-bromo-6-substituted penicillanic acid derivatives as beta-lactamase inhibitors. Farmaco 57:663-669.
4. Bell, J., J. Turnidge, and R. N. Jones. 2003. Prevalence of extended-spectrum β-lactamase-producing Enterobacter cloacae in the Asia-Pacific region: results from the SENTRY antimicrobial surveillance program, 1998 to 2001. Antimicrob. Agents Chemother. 47:3989-3993.
5. Bradford, P. A. 2001, Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev, 14:933-951.
6. Bradford, P. A., and C. C. Sanders. 1993, Use of a predictor panel to evaluate susceptibility test methods proposed for piperacillin-tazobactam. Antimicrob. Agents Chemother. 37:2578-2583.
7. Bush, K. 2002, The impact of beta-lactamases on the development of novel antimicrobial agents. Curr. Opin. Investig. Drugs 3:1284-1290.
8. Bush, K., G. Jacoby, and A. Medeiros. 1995. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39:1211-1233.
9. Buynak, J. D., L. Vogeti, V. R. Doppalapudi, G. M. Solomon, and H. Chen. 2002. Cephalosporin-derived inhibitors of beta-lactamase. Part 4. The C3 substituent. Bioorg. Med. Chem. Lett. 12:1663-1666.
10. Campbell, B., L. Forrester, W. Zahler, and M. Burks. 1984. β-Lactamase activity of purified and partially characterized human renal dipeptidase. J. Biol. Chem. 259:14586-14590.
11. Di Giacomo, B., G. Tarzia, A. Bedini, G. Gatti, F. Bartoccini, C. Balsamini, A. Tontini, W. Baffone, E. Di Modugno, and A. Felici. 2002. Synthesis of new C-6 alkyliden penicillin derivatives as beta-lactamase inhibitors. Farmaco 57:273-283.
12. Gaynes, R. P., and D. H. Culver. 1992. Resistance to imipenem among selected gram-negative bacilli in the United States. Infect. Control Hosp. Epidemiol. 13:10-14.
13. Hoyen, C. M., A. M. Hujer, K. M. Hujer, S. H. Marshall, L. Carias, P. Toltzis, L. B. Rice, and R. A. Bonomo. 2002. A clinical strain of Escherichia coli possessing CMY-2 plasmid-mediated amp C beta-lactamase: an emerging concern in pediatrics? Microb. Drug Resist. 8:329-333.
14. Jamieson, C. E., P. A. Lambert:, and I. N. Simpson. 2003. In vitro activities of novel oxapenems, alone and in combination with ceftazidime, against gram-positive and gram-negative organisms. Antimicrob. Agents Chemother. 47:2615-2618.
15. Jamieson, C. E., P. A. Lambert, and I. N. Simpson. 2003. In vitro and in vivo activities of AM-112, a novel oxapenem. Antimicrob. Agents Chemother. 47:1652-1657.
16. Jones, R. N., and A. L. Barry. 1989. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830). Diagn. Microbiol. Infect. Dis. 12:495-510.
17. Jones, R. N., D. J. Biedenbach, and A. C. Gales. 2003. Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (United States, 1997 to 2000). Int. J. Antimicrob. Agents 21:1-7.
18. Kaur, K., S. A. Adediran, M. J. Lan, and R. F. Pratt. 2003. Inhibition of beta-lactamases by monocyclic acyl phosphonates. Biochemistry 42:1529-1536.
19. Kuck, N. A., N. V. Jacobus, P. J. Petersen, W. J. Weiss, and R. T. Testa. 1989. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Antimicrob. Agents Chemother. 33:1964-1969.
20. Kurokawa, H., N. Shibata, Y. Doi, K. Shibayama, K. Kamachi, T. Yagi, and Y. Arakawa. 2003. A new TEM-derived extended-spectrum beta-lactamase (TEM-91) with an R164C substitution at the Ω-loop confers ceftazidime resistance. Antimicrob. Agents Chemother. 47:2981-2983.
21. Kuzin, A. P., M. Nukaga, Y. Nukaga, A. Hujer, R. A. Bonomo, and J. R. Knox. 2001. Inhibition of the SHV-1 beta-lactamase by sulfones: crystallographic observation of two reaction intermediates with tazobactam. Biochemistry 40:1861-1866.
22. Maiti, S. N., O. A. Phillips, R. G. Micetich, and D. M. Livermore. 1998. Beta-lactamase inhibitors: agents to overcome bacterial resistance. Curr. Med. Chem. 5:441-456.
23. Majiduddin, F. K., and T. Palzkill. 2003. Amino acid sequence requirements at residues 69 and 238 for the SME-1 β-lactamase to confer resistance to β-lactam antibiotics. Antimicrob. Agents Chemother. 47:1062-1067.
24. Miller, L. A., K. Ratnam, and D. J. Payne. 2001. Beta-lactamase-inhibitor combinations in the 21st century: current agents and new developments. Curr. Opin. Pharmacol. 1:451-458.
25. Moosdeen, F., J. D. Williams, and S. Yamabe. 1988. Antibacterial characteristics of YTR 830, a sulfone beta-lactamase inhibitor, compared with those of clavulanic acid and sulbactam. Antimicrob. Agents Chemother. 32:925-927.
26. Morandi, F., E. Caselli, S. Morandi, P. J. Focia, J. Blazquez, B. K. Shoichet, and F. Prati. 2003. Nanomolar inhibitors of AmpC beta-lactamase. J. Am. Chem. Soc. 125:685-695.
27. National Nosocomial Infections Surveillance System. 2002. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 to June 2002, issued August 2002. Am. J. Infect. Control 30:458-475.
28. NCCLS. 1999. Methods for determining bactericidal activity of antimicrobial agents. Approved guidelines: M26-A, vol. 19. NCCLS, Wayne, Pa.
29. NCCLS. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standards: M07-A6, 6th ed., vol. 23. NCCLS, Wayne, Pa.
30. Nukaga, M., T. Abe, A. Venkatesan, T. Mansour, R. A. Bonomo, and J. R. Knox. 2003. Inhibition of class A and class C beta-lactamases by penems: crystallographic structures of novel 1,4-thiazepine intermediate. Biochemistry 42:13152-13159.
31. Nukaga, M., K. Mayama, A. M. Hujer, R. A. Bonomo, and J. R. Knox. 2003. Ultrahigh resolution structure of a class A beta-lactamase: on the mechanism and specificity of the extended-spectrum SHV-2 enzyme. J. Mol. Biol. 328: 289-301.
32. Odeh, R., S. Kelkar, A. M. Hujer, R. A. Bonomo, P. C. Schreckenberger, and J. P. Quinn. 2002. Broad resistance due to plasmid-mediated AmpC beta-lactamases in clinical isolates of Escherichia coli. Clin. Infect. Dis. 35:140-145.
33. Payne, D. J., R. Cramp, D. J. Winstanley, and D. J. Knowles. 1994. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases. Antimicrob. Agents Chemother. 38: 767-772.
34. Rhomberg, P. R., R. N. Jones, and MYSTIC Program Study Group. 2003. Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America. Diagn. Microbiol. Infect. Dis. 47:365-372.
35. She, D., and Y. Liu. 2002. The expression of AmpC and extended-spectrum beta-lactamases among clinical isolates of Enterobacter cloacae and its impact on antibiotics susceptibility. Chin. Med. J. 82:1355-1358.
36. Thomson, K. S., and E. S. Moland. 2000. Version 2000: the new beta-lactamases of Gram-negative bacteria at the dawn of the new millennium. Microbes Infect. 2:1225-1235.
37. Walther-Rasmussen, J., and N. Hoiby. 2002. Plasmid-borne AmpC beta-lactamases. Can. J. Microbiol. 48:479-493.
38. Weiss, W. J., S. M. Mikels, P. J. Petersen, N. V. Jacobus, P. Bitha, Y. I. Lin, and R. T. Testa. 1999. In vivo activities of peptidic prodrugs of novel aminomethyl tetrahydrofuranyl-1 beta-methylcarbapenems. Antimicrob. Agents Chemother. 43:460-464.
39. Yang, Y., N. Bhachech, P. A. Bradford, B. D. Jett, D. F. Sahm, and K. Bush. 1998. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli isolates producing TEM-10 and TEM-43 beta-lactamases from St. Louis, Missouri. Antimicrob. Agents Chemother. 42:1671-1676.
40. Yang, Y., R. T. Testa, N. Bhachech, B. A. Rasmussen, and K. Bush. 1999. Biochemical characterization of novel tetrahydrofuranyl 1β- methylcarbapenems: stability to hydrolysis by renal dehydropeptidases and bacterial β-lactamases, binding to penicillin binding proteins, and permeability properties. Antimicrob. Agents Chemother. 43:2904-2909.